FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2497085418> ?p ?o ?g. }

• W2497085418 endingPage "e15045" @default.
• W2497085418 startingPage "e15045" @default.
• W2497085418 abstract "e15045 Background: Oxaliplatin is effective in many GI cancers, especially colorectal cancer (CRC); however, severe neuropathy develops frequently. PGB is a new antiepileptic drug approved as adjunctive therapy of partial seizures in adults, pain from diabetic neuropathy and post-herpetic neuralgia. PGB is structurally related to gabapentin, but unlike gabapentin, it is well absorbed (> 90%) and its absorption is dose independent. In this study, we evaluated the role of PGB in reduction of oxaliplatin- induced neuropathy. Methods: From Nov 2006 to Dec 2008, a total of 23 pts (age range: 50–71 yrs; M:F = 14:9) with GI cancers were treated with PGB upon development of oxaliplatin-induced neuropathy > G2 (NCI-CTC 3.0). Of these pts, 15 received FOLFOX for CRC, 2 EOX for gastric ca and 6 GemOx for pancreatic ca. Neurologic symptoms were evaluated prior PGB and then q 2 wks. PGB was started at 50mg PO tid, and if tolerated, dose was escalated by 50mg increments until symptoms improved up to a maximum of 150mg PO tid. Results: 5/23 pts (22%) were escalated to 150mg PO tid. 12 pts (52%) were escalated to 100mg tid, out of which 7 (58%) continued, 4 (33%) stopped due to no benefit and 1 (8%) stopped due to weight gain. 1/23 (4%) decided to follow 100mg bid. 5/23 (22%) could not be escalated above 50mg tid; 2 continued at this dose and 3 stopped due to CNS side effects. Onset of benefit was observed in 2 - 6 wks. In 3/23 pts (13%), neuropathy improved from G3 to G2, 2/23 (9%) from G3 to G1, 5/23 (22%) from G2 to G1, 6/23 (26%) remained stable at G2 and no pts remained at G3. Most pts continued PGB even beyond disease progression on oxaliplatin (15/23). Among those who continued (15), duration of therapy was 4 -24 months. The best benefit with PGB was seen at a dose of 150mg tid, followed by 100mg tid. The most common non-hematologic toxicities were dizziness (57%), headache (26%), somnolence (22%), dry mouth (17%), ataxia (17%), tremor (13%), peripheral edema (13%), weight gain (13%), blurred vision (13%) and constipation (9%). Hematologic toxicity (G1 thrombocytopenia) was seen in 1 pt (4%) but impact of chemotherapy could not be excluded. Conclusions: PGB significantly reduces the severity of oxaliplatin-induced neuropathy. Larger, placebo-controlled trials assessing safety and efficacy of oral PGB are warranted in pts treated with oxaliplatin. [Table: see text]" @default.
• W2497085418 created "2016-08-23" @default.
• W2497085418 creator A5032552534 @default.
• W2497085418 creator A5050777825 @default.
• W2497085418 creator A5051448168 @default.
• W2497085418 creator A5062298311 @default.
• W2497085418 creator A5070561439 @default.
• W2497085418 date "2009-05-20" @default.
• W2497085418 modified "2023-10-01" @default.
• W2497085418 title "Pregabalin (PGB) in treatment of oxaliplatin-induced neuropathy" @default.
• W2497085418 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e15045" @default.
• W2497085418 hasPublicationYear "2009" @default.
• W2497085418 type Work @default.
• W2497085418 sameAs 2497085418 @default.
• W2497085418 citedByCount "2" @default.
• W2497085418 countsByYear W24970854182020 @default.
• W2497085418 crossrefType "journal-article" @default.
• W2497085418 hasAuthorship W2497085418A5032552534 @default.
• W2497085418 hasAuthorship W2497085418A5050777825 @default.
• W2497085418 hasAuthorship W2497085418A5051448168 @default.
• W2497085418 hasAuthorship W2497085418A5062298311 @default.
• W2497085418 hasAuthorship W2497085418A5070561439 @default.
• W2497085418 hasConcept C121608353 @default.
• W2497085418 hasConcept C126322002 @default.
• W2497085418 hasConcept C142724271 @default.
• W2497085418 hasConcept C204787440 @default.
• W2497085418 hasConcept C2776468701 @default.
• W2497085418 hasConcept C2776608144 @default.
• W2497085418 hasConcept C2777107010 @default.
• W2497085418 hasConcept C2778260052 @default.
• W2497085418 hasConcept C2780962732 @default.
• W2497085418 hasConcept C42219234 @default.
• W2497085418 hasConcept C526805850 @default.
• W2497085418 hasConcept C71924100 @default.
• W2497085418 hasConcept C90924648 @default.
• W2497085418 hasConceptScore W2497085418C121608353 @default.
• W2497085418 hasConceptScore W2497085418C126322002 @default.
• W2497085418 hasConceptScore W2497085418C142724271 @default.
• W2497085418 hasConceptScore W2497085418C204787440 @default.
• W2497085418 hasConceptScore W2497085418C2776468701 @default.
• W2497085418 hasConceptScore W2497085418C2776608144 @default.
• W2497085418 hasConceptScore W2497085418C2777107010 @default.
• W2497085418 hasConceptScore W2497085418C2778260052 @default.
• W2497085418 hasConceptScore W2497085418C2780962732 @default.
• W2497085418 hasConceptScore W2497085418C42219234 @default.
• W2497085418 hasConceptScore W2497085418C526805850 @default.
• W2497085418 hasConceptScore W2497085418C71924100 @default.
• W2497085418 hasConceptScore W2497085418C90924648 @default.
• W2497085418 hasIssue "15_suppl" @default.
• W2497085418 hasLocation W24970854181 @default.
• W2497085418 hasOpenAccess W2497085418 @default.
• W2497085418 hasPrimaryLocation W24970854181 @default.
• W2497085418 hasRelatedWork W2588594358 @default.
• W2497085418 hasRelatedWork W2919765778 @default.
• W2497085418 hasRelatedWork W2973537373 @default.
• W2497085418 hasRelatedWork W3009717295 @default.
• W2497085418 hasRelatedWork W3011504287 @default.
• W2497085418 hasRelatedWork W3046103354 @default.
• W2497085418 hasRelatedWork W3116165762 @default.
• W2497085418 hasRelatedWork W4292999421 @default.
• W2497085418 hasRelatedWork W4311325658 @default.
• W2497085418 hasRelatedWork W2187299098 @default.
• W2497085418 hasVolume "27" @default.
• W2497085418 isParatext "false" @default.
• W2497085418 isRetracted "false" @default.
• W2497085418 magId "2497085418" @default.
• W2497085418 workType "article" @default.